Other safety alerts
|
| |
| The United Kingdom: Falsified Ozempic (semaglutide) pens identified at two wholesalers in the UK |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that pre-filled pens falsely labelled as the diabetes medicine Ozempic (semaglutide, 1 mg, solution for injection) have been identified at two United Kingdom (UK) wholesalers. All affected pens have been recalled and accounted for, and none of the pens have been supplied to UK patients.
Following investigation, the MHRA has confirmed that the products, under the brand name Ozempic, were brought in from legitimate suppliers in Austria and Germany. The MHRA is working closely with its regulatory partners internationally to continue to maintain the security of the wider supply chain, both at home and abroad.
While the falsified pens appeared to have authentic German packaging, there are substantial differences compared with genuine pens. The German medicines agency, the Federal Institute for Drugs and Medical Devices, has published photos of the genuine and falsified products.
There is no evidence that any of the falsified pens have been dispensed to patients from legitimate pharmacies or healthcare professionals in the UK and there are no reports of harm to patients in relation to these pens.
Please refer to the following website in MHRA for details:
http://www.gov.uk/government/news/falsified-ozempic-semaglutide-pens-identified-at-two-wholesalers-in-the-uk
In Hong Kong, Ozempic Solution For Injection In 3.0ml Pre-filled Pen 1mg/dose (HK-66487) is a pharmaceutical product registered by Novo Nordisk Hong Kong Ltd. The product is a prescription-only medicine. The packaging of the falsified Ozempic pens mentioned in the above MHRA’s announcement is different from the registered packaging of the product in Hong Kong.
Ends/Thursday, Oct 19, 2023
Issued at HKT 14:00
|
| |
|
